PMID: 9558126Apr 29, 1998Paper

A model for the prediction of digoxin-drug interactions at the renal tubular cell level

Therapeutic Drug Monitoring
C WoodlandG Koren

Abstract

Digoxin-drug interactions are relatively common causes of digitalis toxicity. Recently, the clinical importance of the renal tubular secretion of digoxin has been proven by documenting drug interactions at this level. The authors describe a model using cultured renal tubular cell monolayers that can be used to predict drug interactions with the cardiac glycoside. This model accurately documents known clinical digoxin interactions such as those with verapamil and propafenone. The common feature of these interactions is that they involve P-glycoprotein substrates (e.g., digoxin, vincristine, vinblastine) or inhibitors (e.g., quinidine, cyclosporine). In the case of the newly described interaction of digoxin with itraconazole, the model preceded the emergence of clinical cases.

References

Mar 15, 1992·Annals of Internal Medicine·J Rex
Nov 1, 1992·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·C A Kauffman, F A Bagnasco
Apr 15, 1985·The American Journal of Cardiology·G Koren, R Parker
Jul 1, 1974·Circulation·E Steiness
Jan 1, 1993·Canadian Journal of Physiology and Pharmacology·S ItoM Silverman
Feb 1, 1994·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·K L McClean, G J Sheehan
Mar 1, 1993·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·M K SachsP J Green
Nov 1, 1996·Pharmacology & Toxicology·J PartanenP J Neuvonen
Apr 1, 1997·The Annals of Pharmacotherapy·C P Alderman, P D Allcroft

❮ Previous
Next ❯

Citations

Jul 16, 2003·European Journal of Obstetrics, Gynecology, and Reproductive Biology·Gershon HolcbergZvi Ben-Zvi
Oct 30, 2012·Toxicological Sciences : an Official Journal of the Society of Toxicology·Elnaz GozalpourJan B Koenderink
Feb 28, 2007·Clinical and Experimental Pharmacology & Physiology·Stanislav MicudaJirina Martinkova
Dec 26, 2001·Antimicrobial Agents and Chemotherapy·Er-jia WangWilliam W Johnson
Jul 11, 2001·Pharmacotherapy·C J MathenyG M Pollack
Mar 10, 2000·Clinical Pharmacokinetics·K VenkatakrishnanD J Greenblatt
Mar 3, 2004·Proceedings of the National Academy of Sciences of the United States of America·Tsuyoshi MikkaichiTakaaki Abe
Jul 25, 2006·Expert Opinion on Drug Metabolism & Toxicology·Meng LiJoanne Wang
Dec 21, 2005·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Christopher J EndresJashvant D Unadkat
Feb 13, 2003·British Journal of Clinical Pharmacology·Christer TannergrenHans Lennernäs
Oct 23, 2004·Drug Metabolism and Pharmacokinetics·Tsuyoshi MikkaichiTakaaki Abe
Mar 24, 2016·Antimicrobial Agents and Chemotherapy·Vincent J C LempersJan B Koenderink
Aug 21, 2010·Journal of Pharmacological Sciences·Jeff Hughes, Andrew Crowe
Feb 24, 2001·The Annals of Pharmacotherapy·P A KublerJ R McKay
Sep 19, 2002·Journal of the American Podiatric Medical Association·Arush K Angirasa, Ada Z Koch

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cardiac Glycosides

Cardiac glycosides are a diverse family of naturally derived compounds that bind to and inhibit na+/k+-atpase. Discover the latest research on cardiac glycosides heres.

Related Papers

Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
M K SachsP J Green
Therapeutic Drug Monitoring
K M JalavaP J Neuvonen
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
P Francis, T J Walsh
Clinical and Laboratory Haematology
J GilliesR Soutar
© 2022 Meta ULC. All rights reserved